Inclisiran

Phase 3

Novartis AG (NVS)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

NVSPhase 3$271.5B

Inclisiran Phase 3 Est. Readout

Inclisiran• Familial Hypercholesterolemia - Homozygous300

Feb 2027~Estimated

CT.gov

00%

Development History

Oct '26

NVSPhase 3$271.5B

Inclisiran Phase 3 Est. Readout

Inclisiran• Familial Hypercholesterolemia - Homozygous16,124

Oct 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Familial Hypercholesterolemia - Homozygous

View Full Landscape

Drug Information

Target Indication

Familial Hypercholesterolemia - Homozygous

Clinical Trial

NCT06597006

Last updated: 1/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Benazepril plus hydrochlorothiazidePhase 3

Hypertension

Verteporfin PDTPhase 3

Pathological Myopia

Certican®Phase 3

Renal Interstitial Fibrosis

lisinoprilPhase 3

Hypertension

[68Ga]Ga-PSMA-11Phase 3

Prostatic Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts